These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24468835)

  • 61. Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allogenic hematopoietic stem cell transplantation: a systematic approach.
    Kreft A; Neumann H; Schindeldecker M; Wagner-Drouet EM
    Leuk Lymphoma; 2019 Jun; 60(6):1512-1521. PubMed ID: 30632829
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.
    Blazar BR; Hill GR; Murphy WJ
    Nat Rev Clin Oncol; 2020 Aug; 17(8):475-492. PubMed ID: 32313224
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
    Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
    Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
    Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
    Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
    Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevention of graft-vs.-host disease.
    Rezvani AR; Storb RF
    Expert Opin Pharmacother; 2012 Aug; 13(12):1737-50. PubMed ID: 22770714
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
    Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
    Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease.
    Almici C; Skert C; Verardi R; Di Palma A; Bianchetti A; Neva A; Braga S; Malagola M; Turra A; Marini M; Russo D
    Transplantation; 2014 Oct; 98(7):706-12. PubMed ID: 25119132
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [GVHD: pathophysiology and novel agents].
    Ara T; Hashimoto D
    Rinsho Ketsueki; 2022; 63(9):1261-1269. PubMed ID: 36198552
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Advances in understanding the pathogenesis of graft-versus-host disease.
    Magenau J; Runaas L; Reddy P
    Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
    Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
    Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
    Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
    Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
    Pavletic SZ; Kumar S; Mohty M; de Lima M; Foran JM; Pasquini M; Zhang MJ; Giralt S; Bishop MR; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):871-90. PubMed ID: 20399876
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
    Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
    Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.